UK markets closed

NuCana plc (NCNA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.6400+0.0100 (+0.28%)
As of 02:08PM EDT. Market open.

NuCana plc

3 Lochside Way
Edinburgh EH12 9DT
United Kingdom
44 13 1357 1111
https://www.nucana.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees25

Key executives

NameTitlePayExercisedYear born
Mr. Hugh Stephen GriffithFounder, CEO & Executive Director1.24MN/A1968
Mr. Donald MunozChief Financial OfficerN/AN/A1969
Mr. David HarrisonHead of Translational MedicineN/AN/A1960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.Chief Medical OfficerN/AN/A1958
Ms. Theresa BruceSenior Vice President of Clinical OperationsN/AN/AN/A
Ms. Elisabeth OelmannSenior Vice President of Medical & Clinical DevelopmentN/AN/AN/A
Martin QuinnCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Corporate governance

NuCana plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.